Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of a 4-dose Regimen of PCV21 in Healthy Infants and Toddlers
NCT06824194Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2025
- Primary completion
- Oct 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of PCV21 in pneumococcal infection (2 arms), sponsored by Sanofi. Primary endpoints: Immediate Adverse Events at 30 minutes, Solicited Injection Site and Systemic Reactions at 7 days and 3 more. Started Feb 2025; status: active, not recruiting.
02
Drugs
PCV21
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06824194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824194.